{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:07:08Z","timestamp":1787314028448,"version":"build-2736575974"},"reference-count":25,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000042","name":"Amgen Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>In United Arab Emirates, cardiovascular disease (CVD) is a leading cause of mortality and 22% of CVD deaths are attributable to acute myocardial infarction (MI). Adherence to guidelines for lipid management is incompletely described in the Middle East. This study aimed to characterize lipid lowering therapy (LLT) patterns and the risk of subsequent cardiovascular events (CVEs) in the first year after MI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective cohort study using the Dubai Real-World Claims Database, including all patients discharged with MI between January 01, 2015 and December 31, 2018, followed-up until December 31, 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the first year after MI, 8.42% of 4,595 patients included experienced at least one recurrent MI (rate 6.77 events\/100 person-years [PYs]), 2.94% had one revascularization (cumulative rate 0.55 events\/100 PYs) and 2.66% had one hospitalization due to unstable angina (cumulative rate 5.16 new events\/100 PYs). The majority (60.40%) of the patients presented with LDL-C levels \u2265 70 mg\/dL after MI. In the first year after MI, 93.45% of the patients received LLT, mainly high-intensity statin (67.79%); with a minority of patients receiving statin + ezetimibe (4.55%), PCSK9i (0.20%) or ezetimibe alone (0.07%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients hospitalized with MI in Dubai present an increased risk of CVEs in their first-year post-discharge. Majority of the patients presented with LDL-C levels above 70 mg\/dL, which indicates suboptimal lipid control with existing LLT, particularly in high-risk patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0268709","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T13:38:27Z","timestamp":1662125907000},"page":"e0268709","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Lipid lowering therapy patterns and the risk of cardiovascular events in the 1-year after acute myocardial infarction in United Arab Emirates"],"prefix":"10.1371","volume":"17","author":[{"given":"Lionel","family":"Pinto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Farghaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasikiran","family":"Nunna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9965-1492","authenticated-orcid":true,"given":"Badarinath","family":"Chickballapur Ramachandrachar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Harshadeep","family":"Chilukuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9435-1300","authenticated-orcid":true,"given":"Ashok","family":"Natarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"pone.0268709.ref001","unstructured":"WHO. World Health Organization, Cardiovascular Diseases (CVDs), Fact Sheet, https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds) (2017, accessed 25 Aug 2019)."},{"key":"pone.0268709.ref002","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.atherosclerosis.2016.07.925","article-title":"Dyslipidaemia in the Middle East: Current status and a call for action","volume":"252","author":"K Al Rasadi","year":"2016","journal-title":"Atherosclerosis"},{"issue":"3_suppl","key":"pone.0268709.ref003","first-page":"83S","volume":"22","author":"TM Ramahi","year":"2010","journal-title":"Cardiovascular Disease in the Asia Middle East Region: Global Trends and Local Implications"},{"issue":"3","key":"pone.0268709.ref004","first-page":"105","volume":"11","author":"H Razzak","year":"2018","journal-title":"Prevalence and risk factors of cardiovascular disease in the United Arab Emirates"},{"issue":"1","key":"pone.0268709.ref005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5144\/0256-4947.2012.9","article-title":"Baseline characteristics, management practices, and long-term outcomes of Middle Eastern patients in the Second Gulf Registry of Acute Coronary Events (Gulf RACE-2)","volume":"32","author":"KF Alhabib","year":"2012","journal-title":"Ann Saudi Med"},{"issue":"4","key":"pone.0268709.ref006","doi-asserted-by":"crossref","first-page":"439","DOI":"10.2143\/AC.64.4.2041607","article-title":"Management and outcomes of Middle Eastern patients admitted with acute coronary syndromes in the Gulf Registry of Acute Coronary Events (Gulf RACE)","volume":"64","author":"M Zubaid","year":"2009","journal-title":"Acta Cardiol"},{"issue":"19","key":"pone.0268709.ref007","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","article-title":"Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective","volume":"36","author":"T Jernberg","year":"2015","journal-title":"Eur Heart J"},{"issue":"3","key":"pone.0268709.ref008","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/ehjqcco\/qcw004","article-title":"Using big data from health records from four countries to evaluate chronic disease outcomes: a study in 114 364 survivors of myocardial infarction","volume":"2","author":"E Rapsomaniki","year":"2016","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"issue":"9493","key":"pone.0268709.ref009","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"C Baigent","year":"2005","journal-title":"Lancet"},{"key":"pone.0268709.ref010","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/CVM-2-1-012","article-title":"Debate: \u201cHow low should LDL cholesterol be lowered for optimum prevention of vascular disease?\u201d Viewpoint: \u201cBelow 100 mg\/dl\u201d","volume":"2","author":"WV Brown","year":"2001","journal-title":"Curr Control Trials Cardiovasc Med"},{"issue":"14","key":"pone.0268709.ref011","first-page":"1425","volume":"352","author":"JC LaRosa","year":"2005","journal-title":"Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease"},{"key":"pone.0268709.ref012","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijcard.2016.09.081","article-title":"Consensus clinical recommendations for the management of plasma lipid disorders in the Middle East","volume":"225","author":"N Al Sayed","year":"2016","journal-title":"Int J Cardiol"},{"issue":"8","key":"pone.0268709.ref013","doi-asserted-by":"crossref","first-page":"e102830","DOI":"10.1371\/journal.pone.0102830","article-title":"Cardiovascular risk factor burden in Africa and the Middle East: the Africa Middle East Cardiovascular Epidemiological (ACE) study","volume":"9","author":"AA Alsheikh-Ali","year":"2014","journal-title":"PLoS One"},{"issue":"10059","key":"pone.0268709.ref014","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"R Collins","year":"2016","journal-title":"Lancet"},{"issue":"7","key":"pone.0268709.ref015","doi-asserted-by":"crossref","first-page":"e0180010","DOI":"10.1371\/journal.pone.0180010","article-title":"Long term health outcomes in patients with a history of myocardial infarction: A population based cohort study","volume":"12","author":"N Tangri","year":"2017","journal-title":"PLoS One"},{"issue":"11_Supplement","key":"pone.0268709.ref016","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0735-1097(17)33572-6","article-title":"Incidence of recurrent myocardial infarction among older adults in US Community practice","volume":"69","author":"A Kochar","year":"2017","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"pone.0268709.ref017","doi-asserted-by":"crossref","first-page":"e014402","DOI":"10.1161\/JAHA.119.014402","article-title":"Incidence and Predictors of Major Adverse Cardiovascular Events in Patients With Established Atherosclerotic Disease or Multiple Risk Factors","volume":"9","author":"B Miao","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"24","key":"pone.0268709.ref018","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"SM Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"pone.0268709.ref019","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1136\/heartjnl-2018-314253","article-title":"Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease","volume":"105","author":"RK Akyea","year":"2019","journal-title":"Heart"},{"key":"pone.0268709.ref020","doi-asserted-by":"crossref","first-page":"861924","DOI":"10.1155\/2012\/861924","article-title":"Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients","volume":"2012","author":"DG Karalis","year":"2012","journal-title":"Cholesterol"},{"issue":"3","key":"pone.0268709.ref021","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jacl.2010.03.002","article-title":"Attainment of low-density lipoprotein cholesterol goals in coronary artery disease","volume":"4","author":"AB Kauffman","year":"2010","journal-title":"J Clin Lipidol"},{"key":"pone.0268709.ref022","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.atherosclerosis.2016.07.001","article-title":"Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: An analysis of more than 33,000 high cardiovascular risk patients in Japan","volume":"251","author":"T Teramoto","year":"2016","journal-title":"Atherosclerosis"},{"issue":"8","key":"pone.0268709.ref023","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.amjmed.2005.11.015","article-title":"Contemporary management of dyslipidemia in high-risk patients: targets still not met","volume":"119","author":"AT Yan","year":"2006","journal-title":"Am J Med"},{"issue":"12","key":"pone.0268709.ref024","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.18553\/jmcp.2017.16414","article-title":"Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia","volume":"23","author":"J Menzin","year":"2017","journal-title":"Journal of managed care & specialty pharmacy"},{"issue":"7","key":"pone.0268709.ref025","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1001\/jamaneurol.2017.0427","article-title":"Ascertainment Bias in Statin Use and Alzheimer Disease Incidence","volume":"74","author":"DM Freedman","year":"2017","journal-title":"JAMA Neurol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0268709","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T13:39:07Z","timestamp":1662125947000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0268709"}},"subtitle":[],"editor":[{"given":"Andreas","family":"Zirlik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0268709","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]}}}